Recent News

• 09.16.2025 - Stifel 2025 Virtual Immunology and Inflammation Forum
• 09.16.2025 - Stifel 2025 Virtual Immunology and Inflammation Forum
• 09.11.2025 - Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress
• 09.11.2025 - Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress
• 09.03.2025 - Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum
• 09.03.2025 - Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum
• 08.11.2025 - Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
• 08.11.2025 - Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
• 07.07.2025 - Apogee Therapeutics APEX Phase 2 Part A Readout
• 07.07.2025 - Apogee Therapeutics APEX Phase 2 Part A Readout

Recent Filings

• 09.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.11.2025 - EX-99.1 EX-99.1
• 08.11.2025 - 8-K Current report
• 08.11.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.08.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.06.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.05.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.05.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.16.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors